A survival-stratification model of human colorectal carcinomas with β-catenin and p27kip1

Cancer

Volumn 95, Issue 12, 2002, Pages 2479-2486

  Cheah, Peh Yean ^a   Choo, Poh Heok ^a   Yao, Jocelyn ^a   Eu, Kong Weng ^a   Seow Choen, Francis ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

catenin; Colorectal carcinoma; P27kip1; Prognosis; Risk stratification

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MEMBRANE; CELL NUCLEUS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOGENE; ONCOGENE C MYC; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; UPREGULATION;

ADENOCARCINOMA; BETA CATENIN; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOSKELETAL PROTEINS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0037114729     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10986     Document Type: Article

References (37)

1. Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer incidence in Singapore 1993-1997. Singapore Cancer Registry. 2000;5:6-14.
2. Bast RC Jr., Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
3. Sieber OM, Tomlinson IP, Lamlum H. The adenomatous polyposis coli (APC) tumor suppressor - Genetics, function and disease. Mol Med Today. 2001;6:462-469.
4. Blenz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2001;103:311-320.
5. He T, Sparks AB, Rago C, et al. Identification of c-Myc as a target of the APC pathway. Science. 1998;281:1509-1512.
6. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422-426.
7. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522-5527.
8. Lin S, Xia W, Wang JC, et al. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000;97:4262-4266.
9. Steeg P, Abrams JS. Cancer prognostics: Past, present and p27. Nat Med. 1997;3:152-154.
10. cip1. EMBO J. 1999;18:5310-5320.
11. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321-5333.
12. kip1 protein: Prognostic implications in primary breast cancer. Nat Med. 1997;3:227-230.
13. kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997;88:625-629.
14. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159:941-945.
15. Yatabe Y, Masuda A, Kosikawa T, et al. p27kip1 in human lung cancers: Differential changes in small-cell and non-small cell lung carcinomas. Cancer Res. 1998;58:1042-1047.
16. Loda M, Cakor B, Tam SW, et al. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-234.
17. Yao J, Eu KW, Seow-Choen F, Cheah PY. Down-regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer. 2000;89:213-216.
18. Harpole DH Jr., Herndon JE II, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995;55:51-56.
19. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997;3:222-225.
20. Dosaka-Akita H, Hommura F, Mishina T, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: Different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res. 2001;61:2500-2504.
21. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. Manual for Staging Cancer. American Joint Committee on Cancer. New York: Lippincott, 1992.
22. Cheah PY, Cao X, Eu KW, Seow-Choen F. NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas. Br J Cancer. 1998;77:1164-1168.
23. kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer. 2000;89:236-241.
24. Arber N, Hisbshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110:669-674.
25. Wijhnoven BPL, Dinjens WNM, Pignatelli M. E-cadherincatenin cell-cell adhesion complex and human cancer. Br J Surg. 2000;87:992-1005.
26. Wiechens N, Fagotto F. CRM1- and Ran-independent nuclear export of β-catenin. Curr Biol. 2001;11:18-27.
27. Eleftheriou A, Yoshida M, Hendersons BR. Nuclear export of human β-catenin can occur independent of CRM1 and the adenomatous polyposis coli tumor suppressor. J Biol Chem. 2001;276:25883-25888.
28. Brabletz T, Jung A, Reu S, et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumour environment. Proc Natl Acad Sci USA. 2001;98:10356-10361.
29. Hugh TJ, Dillion SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: A survival analysis. Br J Cancer. 1999;80:1046-1051.
30. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing JG. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: Relationship with patient survival. Gastroenterology. 1997;112:46-54.
31. Hsu H, Jeng Y, Mao T, Chu J, Lai P, Peng S. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157:763-770.
32. Wong CM, Fan ST, Ng IO. β-Catenin mutation and overexpression in hepatocellular carcinoma. Cancer. 2001;92:136-145.
33. Kolligs FT, Kolligs B, Hajra KM, et al. γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev. 2000;14:1319-1331.
34. Bartkova J, Lukas J, Strauss M, Bartek J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer. 1994;58:568-573.
35. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol. 1999;155:1033-1038.
36. Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic β-catenin and MMP-7 (Matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology. 2002;122:60-71.
37. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol. 1998;153:681-686.